Myasthenia Gravis Treatment: Options and What to Expect

How is myasthenia gravis treated?

Myasthenia gravis (MG) is a long-term autoimmune condition. The immune system, which normally fights germs, makes antibodies that block the signal between nerves and muscles — so muscles tire and weaken. There is no cure yet, so treatment has two main jobs: improve the nerve-to-muscle signal so muscles work better, and calm the immune attack that causes the problem.

There’s no single treatment for everyone. Your plan depends on how severe the MG is, which muscles are affected, the type of antibody you have, and your age and other health conditions. Care is usually led by a neurologist and adjusted over time. The good news: with modern treatment, most people improve a lot, and many can expect a near-normal life span.

Medicine to boost muscle strength

The usual first step is pyridostigmine (brand name Mestinon). It doesn’t calm the immune system — instead, it increases the amount of the chemical messenger that carries signals from nerves to muscles, which improves strength for a few hours at a time.

Pyridostigmine is taken as a tablet several times a day. It often helps with day-to-day symptoms, but for many people it isn’t enough on its own, so other treatments are added.

Calming the immune system

Because MG is driven by the immune system, most people also need medicine to quiet it down. These are usually the next step after pyridostigmine:

• Corticosteroids (such as prednisone). Very effective — most people improve — but long-term, high doses can cause side effects like weight gain, thinning bones, mood changes, and higher infection risk, so doctors aim to lower the dose over time.
• Steroid-sparing medicines. Drugs such as azathioprine and mycophenolate mofetil (CellCept), and sometimes cyclosporine, tacrolimus, or methotrexate, help control MG so the steroid dose can come down. These work slowly and may take months to reach full effect.

These medicines require regular blood tests to watch for side effects.

Thymectomy (surgery to remove the thymus)

The thymus, a small gland in the chest, is part of the immune system and is often involved in MG. Removing it — a surgery called a thymectomy — can improve symptoms and sometimes lead to remission. It’s most often considered for people who have AChR antibodies (the most common type in MG) or a thymus tumor called a thymoma. Benefits can take up to a couple of years to appear.

Fast-acting treatments for flares and crises

When symptoms worsen quickly — or during a myasthenic crisis, when the breathing muscles become dangerously weak — doctors use rapid treatments that work within days:

• Intravenous immunoglobulin (IVIG). A concentrated dose of antibodies from healthy donors, given by infusion, that helps reset the immune response.
• Plasma exchange (plasmapheresis). A procedure that filters the harmful antibodies out of the blood.

Both give short-term relief and are often used to stabilize someone during a severe episode. A myasthenic crisis is a medical emergency — call 911 for sudden, severe trouble breathing.

Newer targeted therapies

In the last few years, a new generation of medicines has changed the picture for people whose generalized MG isn’t controlled by standard treatment. Instead of broadly suppressing the immune system, these drugs target specific steps in the disease. They’re usually added to existing treatment rather than replacing it, and most are given by infusion or injection.

• FcRn inhibitors. These lower the level of the harmful antibodies that cause MG. Examples approved in the U.S. include efgartigimod (Vyvgart), rozanolixizumab (Rystiggo), and nipocalimab (Imaavy).
• Complement inhibitors. These block part of the immune system (the complement pathway) that damages the nerve-muscle connection. Examples include eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq). They can raise the risk of serious infections, so vaccinations are important.
• B-cell therapy. A newer approach targets the immune cells that make the harmful antibodies. Inebilizumab (Uplizna) was FDA-approved for generalized MG in late 2025.

These options are typically reserved for MG that stays active despite standard medicines. This field is moving quickly, and more treatments are expected — so it’s worth asking your neurologist what’s newly available.